Physicians' and pharmacists' perception and practice of hospital pharmacist professional role in Egypt.

OBJECTIVES: This study aimed to investigate physicians' and pharmacists' perceptions of the importance of pharmacists' role in healthcare in Egypt, and actual delivery of these roles in practice. Identifying any differences and inconsistencies between these will inform future strategies that maximize pharmacists' professional contribution to hospital practice. METHODS: A self-administered questionnaire using a 5-point Likert scale was distributed to a convenience sample of physicians (500) and pharmacists (500) practicing in selected private or public hospitals in Egypt. The main sections of the questionnaire comprised statements that pertained to physicians'/pharmacists' views on the importance of pharmacists' roles and their actual delivery in practice. KEY FINDINGS: In this study, physicians showed low scores for both the importance of and the delivery of advanced patient-facing clinical pharmacy roles such as suggesting prescription medications, and designing treatment plans. In comparison, pharmacists were more positive on both of these aspects of their roles. High mean scores were reported by the physicians for pharmacist's traditional roles such as patient counselling, assessing compliance, preventing medication errors and treating minor illnesses. Both physicians and pharmacists reported poor pharmacists practice as drug information resources despite their high perception of the importance of that role. CONCLUSION: This study suggested that in hospitals in Egypt, there are significant differences between physicians' and pharmacists' perception and practice, and pharmacists' clinical skills are underutilized in health care.

Telepharmacy for remote hospital inpatients in north-west Queensland.

Clinical pharmacy service delivery is currently a significant challenge in remote areas. Mount Isa Base Hospital provides clinical pharmacy support to ten remote sites across an area of over 300,000 square kilometres. These sites do not have on-site pharmacists available and, due to the vast distances and unpredictable travel conditions, the outreach pharmacist from Mount Isa Base Hospital only visits sporadically. Provision of direct patient care and advice on medication safety with this model was restricted and insufficient. Telepharmacy provides an opportunity for these services to be vastly expanded. In an attempt to increase pharmacist accessibility for remote hospital sites, the Mount Isa Base Hospital pharmacy department developed an inpatient telepharmacy service. Telehealth equipment is being used to communicate directly with patients and hospital staff, review inpatient medication charts, generate patient medication lists, identify and resolve clinical interventions and provide medication-related advice and counselling. As a result of this implementation, all patients and health professionals in remote north-west Queensland hospitals now have access to a pharmacist. The number of inpatient medication reviews, clinical interventions and patient-pharmacist/clinician-pharmacist interactions occurring at each remote hospital site has increased. Since service initiation, 106 medication-related reviews have been completed via telepharmacy, including 48 patient interactions, and 111 medication-related interventions have been made. This paper outlines the process for the development of an inpatient telepharmacy service for remote hospitals and discusses the benefits and limitations associated with implementation.

Development and feasibility of the misuse, abuse, and diversion drug event reporting system (MADDERS®).

BACKGROUND AND OBJECTIVES: Inappropriate use of analgesic drugs has become increasingly pervasive over the past decade. Currently, drug abuse potential is primarily assessed post-marketing; no validated tools are available to assess this potential in phase II and III clinical trials. This paper describes the development and feasibility testing of a Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS), which aims to identify potentially abuse-related events and classify them according to a recently developed classification scheme, allowing the quantification of these events in clinical trials. METHODS: The system was initially conceived and designed with input from experts and patients, followed by field-testing to assess its feasibility and content validity in both completed and ongoing clinical trials. RESULTS: The results suggest that MADDERS is a feasible system with initial validity. It showed higher rates of the triggering events in subjects taking medications with known abuse potential than in patients taking medications without abuse potential. Additionally, experts agreed on the classification of most abuse-related events in MADDERS. DISCUSSION AND CONCLUSIONS: MADDERS is a new systematic approach to collect information on potentially abuse-related events in clinical trials and classify them. The system has demonstrated feasibility for implementation. Additional research is ongoing to further evaluate its validity. SCIENTIFIC SIGNIFICANCE: Currently, there are no validated tools to assess drug abuse potential during clinical trials. Because of its ease of implementation, its systematic approach, and its preliminary validation results, MADDERS could provide such a tool for clinical trials. (Am J Addict 2016;25:641-651).

[Italian physician's needs for medical information. Retrospective analysis of the medical information service provided by Novartis Pharma to clinicians]. / I bisogni informativi dei medici italiani Analisi retrospettiva del servizio di medical information offerto da Novartis Farma ai clinici.

The physician's need for medical information updates has been studied extensively in recent years but the point of view of the pharmaceutical industry on this need has rarely been considered. This paper reports the results of a retrospective analysis of the medical information service provided to Italian physicians by an important pharmaceutical company, Novartis Pharma, from 2004 to 2012. The results confirm clinicians' appreciation of a service that gives them access to tailored scientific documentation and the number of requests made to the network of medical representatives has been rising steadily, peaking whenever new drugs become available to physicians. The analysis confirms what -other international studies have ascertained, that most queries are about how to use the drugs and what their properties are. The results highlight some differences between different medical specialties: for example, proportionally, neurologists seem to be the most curious. This, as well as other interesting snippets, is worth further exploration. Despite its limits in terms of representativeness, what comes out of the study is the existence of an real unmet need for information by healthcare institutions and that the support offered by the pharmaceutical industry could be invaluable; its role could go well beyond that of a mere supplier to National Healthcare Systems, to that of being recognised as an active partner the process of ensuring balanced and evidence-based information. At the same time, closer appraisal of clinicians' needs could help the pharma industries to improve their communication and educational strategies in presenting their latest clinical research and their own products.

A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis.

BACKGROUND: Medication errors are common in primary care and are associated with considerable risk of patient harm. We tested whether a pharmacist-led, information technology-based intervention was more effective than simple feedback in reducing the number of patients at risk of measures related to hazardous prescribing and inadequate blood-test monitoring of medicines 6 months after the intervention. METHODS: In this pragmatic, cluster randomised trial general practices in the UK were stratified by research site and list size, and randomly assigned by a web-based randomisation service in block sizes of two or four to one of two groups. The practices were allocated to either computer-generated simple feedback for at-risk patients (control) or a pharmacist-led information technology intervention (PINCER), composed of feedback, educational outreach, and dedicated support. The allocation was masked to researchers and statisticians involved in processing and analysing the data. The allocation was not masked to general practices, pharmacists, patients, or researchers who visited practices to extract data. [corrected]. Primary outcomes were the proportions of patients at 6 months after the intervention who had had any of three clinically important errors: non-selective non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to those with a history of peptic ulcer without co-prescription of a proton-pump inhibitor; ß blockers prescribed to those with a history of asthma; long-term prescription of angiotensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment of urea and electrolytes in the preceding 15 months. The cost per error avoided was estimated by incremental cost-effectiveness analysis. This study is registered with Controlled-Trials.com, number ISRCTN21785299. FINDINGS: 72 general practices with a combined list size of 480,942 patients were randomised. At 6 months' follow-up, patients in the PINCER group were significantly less likely to have been prescribed a non-selective NSAID if they had a history of peptic ulcer without gastroprotection (OR 0·58, 95% CI 0·38-0·89); a ß blocker if they had asthma (0·73, 0·58-0·91); or an ACE inhibitor or loop diuretic without appropriate monitoring (0·51, 0·34-0·78). PINCER has a 95% probability of being cost effective if the decision-maker's ceiling willingness to pay reaches £75 per error avoided at 6 months. INTERPRETATION: The PINCER intervention is an effective method for reducing a range of medication errors in general practices with computerised clinical records. FUNDING: Patient Safety Research Portfolio, Department of Health, England.

Addiction research centres and the nurturing of creativity. Monitoring the European drug situation: the ongoing challenge for the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the designated hub for drug-related information in the European Union. The organization's role is to provide the European Union (EU) and its Member States with a factual overview of European drug problems and a common information framework to support the drugs debate. In order to achieve its mission, the EMCDDA coordinates and relies on a network of 30 national monitoring centres, the Reitox National Focal Points. The Centre publishes on a wide range of drug-related topics, across epidemiology, interventions, laws and policies. Every November, the EMCDDA publishes its Annual Report, providing a yearly update on the European drug situation, translated into 23 EU languages. In line with its founding regulation, the EMCDDA has a role acting as an interface between the worlds of science and policy. While not a research centre in the formal sense, the results the Centre generates serve as catalysts for new research questions and help to identify priorities. Current challenges facing the agency include continuing to increase scientific standards while maintaining a strong institutional role, as well as supporting European efforts to identify, share and codify best practice in the drugs field.

Drug dispensing and information giving in Belo Horizonte, Brazil.

PURPOSE: The purpose of this paper is to examine drug dispensing and associated activity in Belo Horizonte, Brazil. The paper aims to describe factors associated with patient information giving and dispensing time. DESIGN/METHODOLOGY/APPROACH: A specific protocol for recording data gathered from observations included: number of dispensing sessions; medical specialties active at the time; medication number and type; dispensing outcome; if information giving was observed and dispensing time. Information giving and time were considered response variables. The chi-square test and odds-ratios were used to verify associations between response and explanatory variables. FINDINGS: In 43 percent (45) consultations, information giving accompanied dispensing and was associated with number of dispensing sessions and medical specialty offered on a particular day. Assistance time was associated with drug type and number, which increased as dispensing sessions decreased. RESEARCH LIMITATIONS/IMPLICATIONS: Seasonal variations in the demand for pharmacy assistance were not investigated and sample size precluded multivariate analyses. Consequently, new studies may deepen understanding about communication between physicians, pharmacy assistants and users. PRACTICAL IMPLICATIONS: Pharmacy staff could improve quality and efficiency if two aspects were taken into account: fluctuating workload, and external conditions within which tasks are undertaken. ORIGINALITY/VALUE: The paper identifies external conditions that interfere with drug dispensing.

Utility and value of a medicines information service provided by pharmacists: a survey of health professionals.

OBJECTIVES: many health professionals lack the time and skills to search for and appraise information on medicines. A solution might be to use others skilled in evidence appraisal, who make recommendations or provide information tailored to patients' needs. The objectives of this study were to assess how advice provided to health professionals by the northwest of England regional medicines information centre is used, whether it is useful for patient care and to measure satisfaction with the service. METHODS: a questionnaire was designed and sent to health professionals who contacted the centre between September 2008 and March 2009. Enquirers contacting the centre more than once were sent a questionnaire only in response to their first enquiry during the study period. Non-responders were sent a reminder. KEY FINDINGS: questionnaires were sent to 672 enquirers; 68% were returned. Nearly all respondents used the advice provided. Of the 430 respondents who provided data on how they used the information, 81% used it to manage a current patient and 29% to plan the care of future patients; nearly all considered it useful. Where data were given (n = 366), half used it to check if current or proposed management was appropriate, 45% to make changes to therapy and 35% to advise another health professional. In addition to patient care, one-quarter (n = 105/430) of respondents used the information for continuing professional development and 16% (n = 69/430) for training or teaching. CONCLUSIONS: health professionals value the enquiry-answering service and use the advice provided for patient care, continuing professional development and educating patients and other health professionals. The service is responsive, supporting the care of patients needing immediate and future management.

Indicators of rational drug use and health services in Hadramout, Yemen.

WHO standard indicators of rational drug use, this study analysed 550 prescriptions from 20 health facilities at different levels throughout Hadramout governorate, Yemen. A mean of 2.8 (SD 0.2) drugs were prescribed per prescription, with a low rate of prescribing drugs by generic name (39.2%). The proportion of prescriptions for antibiotics was 66.2%, for injectable drugs 46.0% and for vitamins/tonics 23.6%. The essential drugs list was available in 78.9% of facilities and a high percentage of drugs were prescribed from the list (81.2%). Other official sources of local drug information were less available.

Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices.

BACKGROUND: Medication errors are an important cause of morbidity and mortality in primary care. The aims of this study are to determine the effectiveness, cost effectiveness and acceptability of a pharmacist-led information-technology-based complex intervention compared with simple feedback in reducing proportions of patients at risk from potentially hazardous prescribing and medicines management in general (family) practice. METHODS: RESEARCH SUBJECT GROUP: "At-risk" patients registered with computerised general practices in two geographical regions in England. DESIGN: Parallel group pragmatic cluster randomised trial. INTERVENTIONS: Practices will be randomised to either: (i) Computer-generated feedback; or (ii) Pharmacist-led intervention comprising of computer-generated feedback, educational outreach and dedicated support. PRIMARY OUTCOME MEASURES: The proportion of patients in each practice at six and 12 months post intervention: - with a computer-recorded history of peptic ulcer being prescribed non-selective non-steroidal anti-inflammatory drugs; - with a computer-recorded diagnosis of asthma being prescribed beta-blockers; - aged 75 years and older receiving long-term prescriptions for angiotensin converting enzyme inhibitors or loop diuretics without a recorded assessment of renal function and electrolytes in the preceding 15 months. SECONDARY OUTCOME MEASURES; These relate to a number of other examples of potentially hazardous prescribing and medicines management. ECONOMIC ANALYSIS: An economic evaluation will be done of the cost per error avoided, from the perspective of the UK National Health Service (NHS), comparing the pharmacist-led intervention with simple feedback. QUALITATIVE ANALYSIS: A qualitative study will be conducted to explore the views and experiences of health care professionals and NHS managers concerning the interventions, and investigate possible reasons why the interventions prove effective, or conversely prove ineffective. SAMPLE SIZE: 34 practices in each of the two treatment arms would provide at least 80% power (two-tailed alpha of 0.05) to demonstrate a 50% reduction in error rates for each of the three primary outcome measures in the pharmacist-led intervention arm compared with a 11% reduction in the simple feedback arm. DISCUSSION: At the time of submission of this article, 72 general practices have been recruited (36 in each arm of the trial) and the interventions have been delivered. Analysis has not yet been undertaken.

[Importance of the Teratogen Information Service in Bahia, Brazil, for prevention of congenital malformations: an initial four-year review]. / A importância do Serviço de Informações sobre Agentes Teratogênicos, Bahia, Brasil, na prevenção de malformações congênitas: análise dos quatro primeiros anos de funcionamento.

Teratogenic agents are defined as physical, chemical, or biological agents or nutrient deficiencies that lead to fetal structural or functional alterations. Information on the effects of exposure to teratogens during pregnancy is of the utmost importance. In order to achieve this goal, in 2001, the Bahia State Teratogen Information Service was created in the Medical Genetics Department at the University Hospital of the Federal University in Bahia. The current paper aimed to describe the first four years of operation in the service. From March 2001 to May 2005, the service was consulted by telephone, fax, and e-mail. During this period, 408 queries were made, for a total of 1,091 different reasons. Most queries were made by pregnant women and health care professionals. Hair products, herbal teas, and misoprostol were the most widely investigated agents. The low number of queries (average 1/day) shows the need for more awareness-raising on the risks posed by the various agents.

A importância do Serviço de Informações sobre Agentes Teratogênicos, Bahia, Brasil, na prevenção de malformações congênitas: análise dos quatro primeiros anos de funcionamento / Importance of the Teratogen Information Service in Bahia, Brazil, for prevention of congenital malformations: an initial four-year review

Agente teratogênico é definido como o agente físico, químico, biológico ou estado de deficiência que, durante a vida embrionária, leva a alteração na estrutura ou função do concepto. Informações sobre a conduta a ser tomada no caso de exposições a teratogênicos durante a gestação são imprescindíveis. Com essa finalidade, em 2001, foi implantado o Serviço de Informações sobre Agentes Teratogênicos da Bahia (SIAT-BA), localizado no Serviço de Genética Médica do Hospital Universitário Professor Edgard Santos da Universidade Federal da Bahia. O objetivo é descrever as características do atendimento do SIAT-BA nos seus primeiros quatro anos de funcionamento. As consultas foram realizadas através do contato via telefone, fax ou e-mail, entre março de 2001 e maio de 2005. Nesse período, o SIAT-BA recebeu 408 consultas, totalizando 1.091 motivos. A maioria das consultas foi realizada por gestantes e profissionais de saúde. Produtos para cabelo, chás e misoprostol foram os agentes mais investigados. O pequeno número de consultas (1/dia) indica a necessidade de maior divulgação do serviço e da conscientização da população sobre os riscos oferecidos pelos diversos agentes.

Teratogenic agents are defined as physical, chemical, or biological agents or nutrient deficiencies that lead to fetal structural or functional alterations. Information on the effects of exposure to teratogens during pregnancy is of the utmost importance. In order to achieve this goal, in 2001, the Bahia State Teratogen Information Service was created in the Medical Genetics Department at the University Hospital of the Federal University in Bahia. The current paper aimed to describe the first four years of operation in the service. From March 2001 to May 2005, the service was consulted by telephone, fax, and e-mail. During this period, 408 queries were made, for a total of 1,091 different reasons. Most queries were made by pregnant women and health care professionals. Hair products, herbal teas, and misoprostol were the most widely investigated agents. The low number of queries (average 1/day) shows the need for more awareness-raising on the risks posed by the various agents.

E-detailing: information technology applied to pharmaceutical detailing.

BACKGROUND: E-detailing can be best described as the use of information technology in the field of pharmaceutical detailing. It is becoming highly popular among pharmaceutical companies because it maximizes the time of the sales force, cuts down the cost of detailing and increases physician prescribing. Thus, the application of information technology is proving to be beneficial to both physicians and pharmaceutical companies. When e-detailing was introduced in 1996, it was limited to the US; however, numerous other countries soon adopted this novel approach to detailing and now it is popular in many developed nations. OBJECTIVE: The objective of this paper is to demonstrate the rapid growth of e-detailing in the field of pharmaceutical marketing. METHODS: A review of e-detailing literature was conducted in addition to personal conversations with physicians. RESULTS/CONCLUSION: E-detailing has the potential to reduce marketing costs, increase accessibility to physicians and offer many of the advantages of face-to-face detailing. E-detailing is gaining acceptance among physicians because they can access the information of a pharmaceutical product at their own time and convenience. However, the drug safety aspect of e-detailing has not been examined and e-detailing remains a supplement to traditional detailing and is not yet a replacement to it.